BAYA Stock Chart & Stats
€11.20
-€0.20(-1.75%)
At close: 4:00 PM EDT
€11.20
-€0.20(-1.75%)
Day’s Range― - ―
52-Week Range€6.00 - €13.70
Previous CloseN/A
Volume0.00
Average Volume (3M)638.00
Market Cap
€46.20B
Enterprise Value€82.92K
Total Cash (Recent Filing)€6.66B
Total Debt (Recent Filing)€38.93B
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 04, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding3,929,696,000
10 Day Avg. Volume230
30 Day Avg. Volume638
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.40
Price to Sales (P/S)0.83
P/FCF Ratio18.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.89Price Target Upside24.04% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.1
Revenue Forecast (FY)€45.90B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~59% gross margins indicate durable product economics and pricing power across segments. High underlying margins provide structural capacity to fund R&D, absorb SG&A pressure, and support operating cash flow even if revenue growth softens, preserving long-term resilience.
Positive Operating And Free Cash FlowConsistent positive operating and free cash flow, even while net income is negative, shows the business generates real cash. That cash supports ongoing R&D, working capital, and strategic initiatives and reduces reliance on equity financing for core investments over the medium term.
Diversified Life‑sciences PortfolioA three‑pillar model (Pharmaceuticals, Consumer Health, Crop Science) spreads revenue sources across distinct end markets, lowering single‑market cyclicality. Diversification enables cross‑segment resilience and multiple long‑term growth levers from branded drugs, OTC brands, and agricultural solutions.
Bears Say
Multi‑year Revenue DeclineA ~25% TTM top‑line drop and multiyear revenue decline signal structural demand or portfolio issues. Sustained revenue erosion reduces scale benefits, pressures per‑unit SG&A absorption, and constrains reinvestment capacity, making recovery and margin maintenance harder over the medium term.
Persistent Net LossesConsecutive net losses since 2023 indicate profitability has not yet normalized. Persistent bottom‑line deficits erode retained earnings, weaken return on equity, and limit strategic flexibility for buybacks, dividends, or large M&A without increasing leverage or diluting shareholders.
Elevated LeverageDebt-to-equity near 1.35x raises refinancing and interest‑coverage risk if cash flows weaken. Elevated leverage limits financial flexibility for strategic investments, increases fixed costs, and heightens vulnerability to margin pressure or macro shocks over the next several quarters.
Bayer News
BAYA FAQ
What was Bayer’s price range in the past 12 months?
Bayer lowest stock price was €6.00 and its highest was €13.70 in the past 12 months.
What is Bayer’s market cap?
Bayer’s market cap is €46.20B.
When is Bayer’s upcoming earnings report date?
Bayer’s upcoming earnings report date is Aug 04, 2026 which is in 5 days.
How were Bayer’s earnings last quarter?
Bayer released its earnings results on May 12, 2026. The company reported €0.694 earnings per share for the quarter, beating the consensus estimate of €0.59 by €0.104.
Is Bayer overvalued?
According to Wall Street analysts Bayer’s price is currently Undervalued.
Does Bayer pay dividends?
Bayer does not currently pay dividends.
What is Bayer’s EPS estimate?
Bayer’s EPS estimate is 0.19.
How many shares outstanding does Bayer have?
Bayer has 3,929,696,000 shares outstanding.
What happened to Bayer’s price movement after its last earnings report?
Bayer reported an EPS of €0.694 in its last earnings report, beating expectations of €0.59. Following the earnings report the stock price went up 9.783%.
Which hedge fund is a major shareholder of Bayer?
Currently, no hedge funds are holding shares in DE:BAYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bayer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€13.89 (24.04% Upside)
€13.89 (24.04% Upside)
Blogger Sentiment
Bullish
DE:BAYA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.07%
12-Months-Change
Fundamentals
Return on Equity
0.24%
Trailing 12-Months
Asset Growth
5.46%
Trailing 12-Months
Company Description
Bayer
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
BAYA Company Deck
BAYA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational progress—delivery of raised guidance, improved launch momentum in Pharma, meaningful DSO-driven cost savings, and a reduced net financial debt position in 2025—against substantial legal and cashflow headwinds. Management articulated tangible growth drivers across Crop Science, Pharma and Consumer Health and concrete cost-savings milestones, but also disclosed large litigation provisions (EUR 11.8 billion liabilities), expected negative free cash flow in 2026 due to ~EUR 5 billion litigation-related payouts, projected net debt increase and significant product declines (notably Xarelto and Eylea). Given the mix of strong operational execution and material financial/legal risks that will weigh on near-term cash flow and balance-sheet metrics, the tone of the call is cautiously constructive but realistic about the challenges ahead.View all DE:BAYA earnings summariesBAYA Stock 12 Month Forecast
Average Price Target
€13.89
▲(24.04% Upside)